Action Point Financial Planning’s TG Therapeutics TGTX Stock Holding History

Action Point Financial Planning’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$659	Buy	+13	New	+$532	﹤0.01%	2589

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Action Point Financial Planning's TGTX Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in TG Therapeutics (TGTX) in Q2 2026: 13 shares worth $659. The stake represents ﹤0.01% of the portfolio and ranks #2589 among its holdings.

426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Action Point Financial Planning held 13 shares of TG Therapeutics worth $659 as of Q2 2026.
TG Therapeutics was a new Action Point Financial Planning position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2589 holding.
426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.